LYMPHIR™ Launch: AI-Powered Oncology Treatment Advances
Citius Oncology Accelerates LYMPHIR™ Launch with Verix AI Integration Citius Oncology (Nasdaq: CTOR) is poised to revolutionize treatment for Cutaneous T-Cell Lymphoma (CTCL) with the impending commercial launch of LYMPHIR™, now significantly bolstered by a strategic integration with Verix AI. This collaboration, announced today, aims to optimize the identification of suitable patients and streamline the … Read more